![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase 3b Studies (5 Years post-treatment) to Assess Long-Term Clinical Outcomes in HCV GT1-Infected Patients Treated With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Emily O Dumas, Jeff rey Enejosa, Greg Ball, Yiran B Hu, Melannie Co, Rajvineeth Kumar Pothacamury, Yan Liu,
Nancy Shulman, Thomas Podsadecki
1AbbVie Inc., North Chicago, Illinois, United States
![EASL1.gif](../images/042715/042715-4/EASL1.gif)
![EASL2.gif](../images/042715/042715-4/EASL2.gif)
![EASL3.gif](../images/042715/042715-4/EASL3.gif)
![EASL4.gif](../images/042715/042715-4/EASL4.gif)
![EASL5.gif](../images/042715/042715-4/EASL5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|